Mark Plavsic
Chief Tech/Sci/R&D Officer at AURA BIOSCIENCES, INC.
Net worth: 2 M $ as of 2024-03-30
Profile
Dr. Mark Plavsic is a Chief Technical Officer at Fate Therapeutics, Inc. Dr. Plavsic was previously employed as a Chief Technical Officer by Lysogene SA and a Head- Process Development & Manufacturing by Torque Therapeutics, Inc. He received his graduate degree from the University of Belgrade and a doctorate degree from the University of Belgrade.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
AURA BIOSCIENCES INC
0.26% | 2024-03-14 | 128,515 ( 0.26% ) | 1 M $ | 2024-03-30 |
FATE THERAPEUTICS, INC.
0.12% | 2023-01-09 | 123,705 ( 0.12% ) | 907 995 $ | 2024-03-30 |
Mark Plavsic active positions
| Companies | Position | Start |
|---|---|---|
| AURA BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 2023-10-01 |
TeraPore Technologies, Inc.
 TeraPore Technologies, Inc. Chemicals: SpecialtyProcess Industries TeraPore Technologies, Inc. develops cutting-edge membrane technologies for high-permeability, high-resolution nanofiltration. The company was founded by Rachel Dorin in 2013 and is headquartered in | Director/Board Member | - |
Former positions of Mark Plavsic
| Companies | Position | End |
|---|---|---|
| FATE THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2023-03-05 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Torque Therapeutics, Inc.
 Torque Therapeutics, Inc. BiotechnologyHealth Technology Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
| LYSOGENE | Chief Tech/Sci/R&D Officer | - |
Training of Mark Plavsic
| University of Belgrade | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| AURA BIOSCIENCES, INC. | Health Technology |
| FATE THERAPEUTICS, INC. | Health Technology |
| LYSOGENE | Commercial Services |
| Private companies | 3 |
|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Torque Therapeutics, Inc.
Torque Therapeutics, Inc. BiotechnologyHealth Technology Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA. | Health Technology |
TeraPore Technologies, Inc.
TeraPore Technologies, Inc. Chemicals: SpecialtyProcess Industries TeraPore Technologies, Inc. develops cutting-edge membrane technologies for high-permeability, high-resolution nanofiltration. The company was founded by Rachel Dorin in 2013 and is headquartered in | Process Industries |
- Stock Market
- Insiders
- Mark Plavsic
